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Purpose: Mutations in Cytochrome P450 (CYP1B1) are a predominant cause of congenital glaucoma. This study was
planned with the aim to identify the mutation profile of CYP1B1 in North Indian primary congenital glaucoma (PCG)
patients.
Methods: After ethical clearance, 50 congenital glaucoma patients and 50 ethnically matched controls were recruited in
this study. Genomic DNA was isolated from the blood and trabecular meshwork, and CYP1B1 was screened for the six
most  prevalent  mutations  (termination  at  223  [Ter@223],  Gly61Glu,  Pro193Leu,  Glu229Lys,  Arg368His,  and
Arg390Cys) by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). DNA sequencing was
done to identify other mutations and for confirmation of RFLP positive samples.
Results: On PCR-RFLP, 21/50 cases (42%) were found positive for one or more of these mutations. However, on
sequencing, we found that 23/50 (46%) harbored the CYPIB1 mutations. Ter@223 was found in 18%, p.R390H in 16%,
and p.R368H in 8% of cases. Three novel mutations, p.L24R, p.F190L, and p.G329D, were identified by DNA sequencing.
Leucine, phenylalanine, and glycine are conserved at the 24th, 190th, and 329th position in the CYP1B1 protein in different
species, suggestive of important functions at these loci. Ter@223 was found to be the most prevalent mutation in our
patients while p.R368H was most prevalent in southern India. The difference in frequency and mutation profile may be
due to the heterogeneous Indian population. Pathogenic CYP1B1 mutations impair anterior chamber development and
differentiation by blocking the aqueous outflow and raising intraocular pressure (IOP).
Conclusions: Three novel mutations were identified in this study. Studies of pathogenic sequence variants in CYP1B1 in
different  populations  may  contribute  to  a  better  understanding  of  the  disease  pathogenesis.  This  may  lead  to  the
development of novel therapeutic approaches in the near future.
Primary  congenital  glaucoma  (PCG;  OMIM  231300;
provided in the public domain by the National Center for
Biotechnology Information, Bethesda, MD) is an inherited
ocular  disorder  of  the  trabecular  meshwork  and  anterior
chamber  angle.  This  leads  to  the  impairment  of  aqueous
outflow, increased intraocular pressure (IOP), and optic nerve
damage that can result in permanent vision loss. The term PCG
is reserved for those cases in which the only anatomic defect
observed  is  isolated  trabeculodysgenesis.  It  is  the  second
largest cause of blindness, accounting for 15% of cases of
blindness.  The  disease  manifests  in  the  neonatal  or  early
infantile period with symptoms of enlargement of the globe,
opacification  of  the  cornea,  and  breaks  in  Descemet’s
membrane  [1].  It  is  characterized  by  the  loss  of  retinal
ganglion  cells  which  leads  to  irreversible  blindness.  It  is
bilateral in 80% of cases. More than 80% of cases present
within first year of life out of which the disease is diagnosed
in the neonatal period in 25% of the cases and within the first
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six months of life in 60% of cases. PCG accounts for 55% of
primary pediatric glaucoma and is the most common type. Its
expression and penetrance varies from 40% to 100%. The
prevalence of PCG varies across ethnic communities ranging
from 1 in 10,000–20,000 in the western populations [2] to 1
in 2,500 and 1 in 1,250 in the Saudi Arabian population [3]
and Gypsy population of Slovakia [2], respectively. In the
Indian state of Andhra Pradesh, prevalence is 1 in 3,300 [4].
The high incidence in the eastern countries is thought to be
due to consanguineous marriages. Early and reliable diagnosis
of the disease is vital, so that appropriate and prompt medical
and surgical interventions can be initiated. This could in turn
prevent visual loss and save vision of the child.
Although there has been much progress in finding new
genes and detecting disease-related mutations, little is known
about  the  function  of  the  mutated  gene  products  and  the
underlying pathogenic mechanisms. Further, it is estimated
that all the known loci/genes of glaucoma account for the
minority of total cases of glaucoma, and hence, many other
genes remain to be identified. Even though three different loci
have been mapped for PCG [5,6], mutations in Cytochrome
P450 (CYP1B1; GLC3A) are the most predominant cause of
disease [7] and are reported in various ethnic backgrounds
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1200[7-10].  An  additional  PCG  locus,  GLC3B  [6],  has  been
mapped to the short arm of chromosome 1 and a third locus,
GLC3C, to 14q24.3, but these genes have not been identified.
Recently, studies showed the association of CYP1B1 with
PCG  in  the  Indian  population  [8].  CYP1B1  is  located  on
chromosome 2 at position p21. The gene contains three exons
and two introns. The three exons of CYP1B1 are 371, 1,044,
and 3,707 base pairs in length, and the two introns are 390 and
3032  base  pairs  in  length.  Both  introns  begin  with  the
sequence GT and end with the sequence AG. The regions
upstream of the 3′ end of the introns are pyrimidine rich. The
coding region of CYP1B1 starts at the 5′ end of the second
exon and ends within the third exon. The putative open reading
frame is 1,629 base pairs in length and codes for a 543 amino
acid protein.
Although  genetic  heterogeneity  has  been  reported  in
PCG,  homogeneity  in  phenotype  as  well  as  genotype
(p.E387K) has been reported in the Slovak Gypsy population,
and common haplotypes (p.G61E, p.D374N, and p.R469W)
have been associated in the Saudi Arabian population [9,10].
Confirmation  of  linkage  between  CYP1B1  and  PCG  in
different  populations  have  verified  the  GLC3A  locus
(CYP1B1) as a major cause of PCG accounting for 85%–90%
of all familial cases and 27% of sporadic cases. CYPIB1-
deficient mice exhibit similar abnormalities in their trabecular
meshwork similar to those in PCG patients.
To date there are very few studies regarding CYP1B1
mutations in PCG patients from northern India. India has a
heterogeneous population with people from north and south
India  being  ethnically  different  (Figure  1).  The  ethno-
linguistic composition of the population of India, Pakistan,
Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka mostly
falls  within  two  large  groups,  Dravidian  and  Indo-Aryan.
These  groups  are  further  subdivided  into  numerous  sub-
groups, castes, and tribes. Indo-Aryans form the predominant
ethno-linguistic group in Pakistan, India (the central, eastern,
western, and northern regions), Nepal, Sri Lanka, and the
Maldives. Dravidians form the predominant ethno-linguistic
group in southern India and the northern and eastern regions
of Sri Lanka [11]. To study the mutation profile of CYP1B1
causing PCG in the north Indian population, we screened
CYP1B1 in 50 new and unrelated cases of north Indian ethnic
background. The data from this preliminary study helped us
to  understand  the  common  mutations  prevalent  in  North
Indian PCG patients, however larger studies are required to
establish a genotype/phenotype correlation.
METHODS
Clinical examination and selection of cases: After approval
from the institutional review board (IRB # IRB00006862; All
India  Institute  of  Medical  Sciences,  Delhi,  India),  50
consecutively  diagnosed  congenital  glaucoma  cases  from
northern  India,  presenting  at  the  Dr.  R.  P.  Centre  for
Ophthalmic  Sciences  (AIIMS,  New  Delhi,  India),  were
enrolled for this study. The diagnosis involved clinical ocular
and  systemic  examination.  All  patients  underwent
ophthalmoscopy  and  tonometry  during  the  screening.
Inclusion  criteria  of  the  patients  were  increased  corneal
diameter  (>12.0  mm),  raised  intraocular  pressure  (>21
mmHg) with presence or absence of Haab’s striae and  optic
disc changes (where examination was possible). Symptoms of
epiphora  and  photophobia  were  the  additional  inclusion
factors. The age of onset ranged from birth to one year. All
cases were sporadic without any history of glaucoma. Fifty
ethnically matched normal individuals without any history of
ocular disorders were enrolled as controls. Peripheral blood
samples were collected from the probands, their relatives, and
controls by venipuncture after informed consent.
Screening of CYP1B1: Genomic DNA was isolated from the
blood and trabecular tissue by the phenol chloroform method.
The DNA isolation kit (Genomic DNA Mini Kit, #GB100;
Geneaid Biotech Ltd., Sijhih City, Taiwan) was used in cases
with  less  sample  (<1  ml).  Mutations  in  CYP1B1  are  the
predominant cause of PCG. The entire coding region (1.6 kb
organized in exons II and III) was screened for mutations.
Using three sets of overlapping primers [8], CYP1B1 was
amplified  from  patients  and  control  subjects.  Mutation
screening  was  done  using  polymerase  chain  reaction-
restriction  fragment  length  polymorphism  (PCR-RFLP)
followed by PCR-DNA sequencing. PCR-RFLP was done for
rapid detection of the six most prevalent mutations: p.G61E,
p.P193L,  p.Ter@223,  p  E229K,  p.R368H,  and  p.R390C
according  to  the  protocol  described  previously  [8].  DNA
sequencing was done in all cases to identify all nucleotide
changes like single nucleotide polymorphisms (SNPs) and
mutations.
PCR-RFLP analyses and cosegregation of mutant alleles with
disease  phenotype:  In  all  RFLP-positive  cases,  mutations
resulted  in  either  loss  or  gain  of  restriction  site.  For
determining the cosegregation of mutant alleles with disease
phenotype in the families, the respective fragments harboring
the  mutation  were  amplified  from  all  available  family
members and RFLP was done as previously described [8]. The
fragments were separated on 2% agarose gel, stained with
ethidium-bromide,  and  visualized  in  ultraviolet  light  to
distinguish the wild type and mutant alleles. DNA sequencing
was done to confirm the mutation.
PCR-DNA sequencing: The whole coding region of CYPB1
was amplified in all cases using already published primers
[12,13], and amplicons were sequenced bidirectionally. The
patient and control sequences were then compared to identify
all mutations. The primers used were set I (1F-1R, 786 bp)
[12], set II (2F-2R, 787 bp) [13], and set III (3F-3R, 885 bp)
[12].  All  PCRs  were  performed  for  only  30  cycles,  and
conditions for sets I and II were as reported earlier [12] while
conditions for set III were initial denaturation at 94 °C for 3
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1201Figure 2. DNA sequence from exon 2 of CYP1B1 equivalent to codon
22-26. A: The reference sequence derived from the control is shown.
B: The sequence derived from PCG 022 shows the homozygous T>G
mutation at genomic position 38159965, which predicts a codon
change from CTG to CGG and L24R mutation.
min followed by 30 cycles each at 94 °C for 30 s, 60 °C for
30 s, and 72 °C for 1 min. PCR was done using previously
described conditions [8].
RESULTS
PCR-RFLP  analysis  of  six  most  prevalent  pathogenic
mutations: PCR-RFLP analyses were performed for all six
mutations  (376insA,  528G→A,  923C→T,  959G→A,
1449G→A,  and  1514C→T).  Out  of  50  patients,  21  were
found positive (homozygous/heterozygous) for one or more
of the above mentioned mutations. All PCR-RFLP-positive
samples  were  subsequently  sequenced  to  confirm  the
mutation. Both p.R390C and p.R390H removed the restriction
site  for  Hin6  restriction  enzyme,  and  DNA  sequencing
confirmed  p.R390H  in  our  patients,  which  has  also  been
reported  from  Pakistan  and  Iran  [13].  Among  the  six
mutations screened, p.Ter@223 was the predominant disease
allele in our patients and 18% of the patients were found to be
heterozygous or homozygous for this mutation. The R390H
Figure  1.  Map  of  India  showing
distribution  of  different  ethnic
populations  in  different  parts  of  the
country.
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1202mutation  (16%)  was  the  next  dominant  disease  allele.
Compound heterozygosity was observed in 10% of the cases
(5/50).
Identification  of  three  novel  missense  mutations  and  one
neutral mutation:
Leucine24Arginine*-Novel  mutation—One  patient
(PCG 022) harbored a novel homozygous missense mutation,
p.  L24R  (GenBank  FJ815437),  in  which  the  nucleotide
thymine (T) was replaced by guanine (G) at genomic position
38159965 and nucleotide position 1432 in the gene (Figure
2). This resulted in a codon change from CTG to CGG in
which a nonpolar amino acid leucine was replaced by a basic
amino acid arginine at position 24 in the polypeptide.
Figure 3. DNA sequence from exon 2 of CYP1B1 equivalent to
codon  187-191. A: The reference sequence derived from control is
shown.  B:  The  sequence  derived  from  PCG  042  shows  the
homozygous C>A mutation at genomic position 38155466, which
predicts a codon change from TTC to TTA and the F190L mutation.
Figure 4. DNA sequence from exon 2nd of CYP1B1 equivalent to
codon  328-331. A: Reference sequence derived from control is
displayed.  B:  The  sequence  derived  from  PCG  043  shows  the
heterozygous G>A mutation at genomic position 38155050, which
predicts a codon change from GGC to GAC and the G329D mutation.
Phenylalanine190Leucine*-Novel  mutation—One
patient (PCG 042) DNA sequencing revealed a change of the
nucleotide cytosine (C) to adenine (A) at genomic position
38155466 and nucleotide position 1931 in the gene (Figure
3). This produced a codon change from TTC to TTA resulting
in  p.  F190L,  a  novel  missense  mutation  (GenBank
FJ815438) replacing amino acid phenylalanine with leucine.
This mutation was found in association with the p. R368H
mutation (homozygous) in the same patient.
Glycine329Aspartic acid*-Novel mutation—Another
patient (PCG 043) DNA sequencing revealed a substitution of
the nucleotide guanine (G) by adenine (A) at genomic position
38155050 and nucleotide position 2347 in the gene (Figure
4), which resulted in a codon change from GGC to GAC
replacing amino acid glycine at position 329 with aspartic
acid. This resulted in a novel missense mutation, p. G329D
(GenBank FJ815439).
Leucine298Leucine—In  another  patient  (PCG  003),
cytosine (C) was substituted by thymine (T), which changed
codon CTC to CTT. This resulted in a synonymous mutation
with no amino acid change. Details of all mutations are given
in Table 1.
Other previously reported mutations:
Missense  mutations—Eight  patients  were  identified
with p.R390H (five homozygous and three heterozygous),
four with p.R368H (two homozygous and two heterozygous),
nine  with  Ter@223  (one  homozygous  and  eight
heterozygous),  five  with  p.E229K  (all  heterozygous)
mutations, and one with a p.M132R homozygous mutation.
Out of these, four patients had compound mutations (Table 1).
The heterozygous p.E229K mutation was detected in five
patients in our study, and Panicker et al. [8] also reported a
similar mutation in heterozygous state in PCG patients.
Compound  heterozygous  mutation—Two  patients
(PCG 034 and PCG 041) were compound heterozygotes for
R390H  and  Ter@223  mutations,  one  (PCG  039)  was
heterozygous for p.R368H and p.Ter@223 mutations, and
two (PCG 036, 045) had p.E229K and p.R390H mutations.
Nonpathogenic CYP1B1 single nucleotide polymorphisms: In
addition to pathogenic mutations, six already reported single
nucleotide  polymorphisms  [8]  were  identified  in  the  less
conserved region of CYP1B1 both in the controls and patients.
These  polymorphisms  were  p.R48G,  p.A119S,  p.L432V,
p.D449D, p.N453S, and rs2617266. They were revealed by
DNA sequencing. rs2617266 (38156104C→T; Figure 5) was
identified  in  two  patients  (PCG  039  and  PCG  040).  All
patients  with  a  CYP1B1  mutation  also  had  L432V
polymorphism.  These  polymorphisms  were  present  in
controls.
On  sequencing,  pathogenic  CYP1B1  mutations  were
identified in 23 patients (46%) but not in controls.
Structural and functional implications of mutant proteins:
Leucine24Arginine (P. L24R)—The first 49 residues
from the NH2-terminal end and the last 16 residues at the
Molecular Vision 2009; 15:1200-1209 <http://www.molvis.org/molvis/v15/a128> © 2009 Molecular Vision
1203T
A
B
L
E
 
1
.
 
D
E
T
A
I
L
S
 
O
F
 
A
L
L
 
C
Y
P
1
B
1
 
M
U
T
A
T
I
O
N
S
.
P
a
t
i
e
n
t
 
I
D
M
u
t
a
t
i
o
n
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
o
r
n
e
a
l
 
D
i
a
m
e
t
e
r
 
(
m
m
)
 
O
S
/
O
D
 
a
n
d
 
c
l
a
r
i
t
y
 
a
t
 
d
i
a
g
n
o
s
i
s
I
O
P
 
l
e
f
t
/
r
i
g
h
t
 
e
y
e
(
m
m
H
g
)
B
u
p
h
t
h
a
l
m
o
s
H
a
a
b
s
’
S
t
r
i
a
e
L
a
s
t
 
C
u
p
/
D
i
s
c
 
r
a
t
i
o
T
r
e
a
t
m
e
n
t
P
C
G
 
0
0
1
R
3
9
0
H
 
(
H
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
5
x
1
5
/
1
5
x
1
5
.
5
;
 
O
U
 
t
o
t
a
l
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c
o
r
n
e
a
l
 
s
c
a
r
r
i
n
g
4
0
/
3
8
O
U
N
o
T
o
t
a
l
 
c
u
p
p
i
n
g
M
e
d
i
c
a
l
 
a
n
d
 
3
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
0
2
R
3
9
0
H
 
(
H
)
1
3
x
1
3
/
1
3
x
1
3
;
 
O
U
 
c
o
r
n
e
a
l
 
e
d
e
m
a
3
6
/
4
0
O
U
N
o
0
.
5
:
1
/
0
.
6
:
!
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
0
3
R
3
9
0
H
 
(
H
)
1
5
x
1
4
/
1
5
x
1
5
;
 
c
l
e
a
r
 
c
o
r
n
e
a
l
2
6
/
3
8
O
U
;
R
>
L
H
a
z
y
 
c
o
r
n
e
a
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
O
U
;
 
1
X
T
r
a
b
/
T
r
a
b
 
O
S
P
C
G
 
0
0
5
R
3
6
8
H
 
(
H
)
1
4
.
5
x
1
5
/
1
5
x
1
5
;
 
O
U
 
c
o
r
n
e
a
l
 
e
d
e
m
a
2
8
/
2
8
O
U
;
L
>
R
N
o
0
.
7
:
1
/
0
.
7
:
1
M
e
d
i
c
a
l
 
a
n
d
 
2
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
1
1
E
2
2
9
K
 
(
h
)
1
4
x
1
4
/
1
4
x
1
5
;
 
c
l
e
a
r
 
c
o
r
n
e
a
2
6
/
2
2
O
U
N
A
N
A
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
1
2
R
3
6
8
H
 
(
h
)
1
4
x
1
4
.
5
/
1
4
x
1
4
.
4
3
2
/
3
2
O
U
O
D
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
1
3
R
3
9
0
H
 
(
H
)
1
4
X
1
4
/
1
4
X
1
4
3
1
/
3
0
O
U
H
a
z
y
 
m
e
d
i
a
M
e
d
i
c
a
l
 
a
n
d
 
2
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
1
4
E
2
2
9
K
 
(
h
)
2
5
/
2
4
O
U
N
o
H
a
z
y
 
m
e
d
i
a
M
e
d
i
c
a
l
 
a
n
d
 
2
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
1
5
M
1
3
2
R
 
(
H
)
1
4
.
5
X
1
4
/
1
3
.
5
X
1
3
3
2
/
3
2
O
U
;
L
>
R
N
o
0
.
6
:
1
O
U
M
e
d
i
c
a
l
 
a
n
d
 
2
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
1
7
T
e
r
@
2
2
3
 
(
H
)
1
4
X
1
4
/
1
4
X
1
4
.
5
3
0
/
2
8
O
U
N
A
M
e
d
i
c
a
l
 
a
n
d
 
2
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
0
1
9
T
e
r
@
2
2
3
 
(
h
)
1
2
X
1
2
.
5
/
1
2
X
1
2
;
 
C
l
e
a
r
 
c
o
r
n
e
a
2
2
/
2
2
O
U
N
o
0
.
5
:
1
 
O
U
M
e
d
i
c
a
l
 
a
n
d
 
2
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
2
1
T
e
r
@
2
2
3
(
h
)
1
5
x
1
6
/
1
1
.
5
x
1
2
;
 
O
S
 
e
d
e
m
a
3
2
/
1
5
O
S
O
U
H
a
z
y
 
m
e
d
i
a
M
e
d
i
c
a
l
 
a
n
d
 
2
X
T
r
a
b
/
T
r
a
b
 
O
S
P
C
G
 
0
2
9
T
e
r
@
2
2
3
 
(
h
)
1
5
x
1
5
/
1
4
x
1
4
;
 
O
U
 
e
d
e
m
a
2
8
/
2
7
O
U
O
U
H
a
x
y
 
m
e
d
i
a
M
e
d
i
c
a
l
 
a
n
d
 
2
X
T
r
a
b
/
T
r
a
b
 
O
S
P
C
G
 
0
2
2
L
2
4
R
 
(
H
)
*
1
5
x
1
5
/
1
6
x
1
6
2
8
/
2
8
O
U
;
R
>
L
O
U
0
.
7
:
1
/
0
.
5
:
1
M
e
d
i
c
a
l
 
a
n
d
 
2
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
3
4
R
3
9
0
H
 
(
h
)
T
e
r
@
2
2
3
 
(
h
)
1
4
x
1
4
/
1
4
x
1
4
2
2
/
2
4
O
D
N
A
N
A
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
D
P
C
G
 
0
3
6
R
3
9
0
H
 
(
H
)
 
E
2
2
9
K
 
(
h
)
1
5
X
1
5
 
O
U
;
 
C
l
e
a
r
 
c
o
r
n
e
a
2
5
/
2
6
O
U
N
o
0
.
8
:
1
 
O
U
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
D
P
C
G
 
0
3
9
R
3
6
8
H
 
(
h
)
T
e
r
@
2
2
3
 
(
h
)
1
3
x
1
3
/
1
2
x
1
3
.
5
;
 
O
U
 
e
d
e
m
a
3
6
/
3
4
O
U
N
o
N
e
a
r
 
t
o
t
a
l
 
c
u
p
p
i
n
g
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
4
0
T
e
r
@
2
2
3
 
(
h
)
1
1
.
5
x
1
2
.
5
/
1
2
x
1
3
;
 
O
U
 
e
d
e
m
a
2
3
/
2
3
O
U
N
o
H
a
z
y
 
m
e
d
i
a
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
D
P
C
G
 
0
4
1
R
3
9
0
H
 
(
H
)
T
e
r
@
2
2
3
 
(
h
)
1
2
x
1
0
/
1
2
x
1
2
.
5
;
 
O
U
 
e
d
e
m
a
4
0
/
2
6
O
U
;
R
>
L
N
o
H
a
z
y
 
m
e
d
i
a
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
4
2
R
3
6
8
H
 
(
H
)
 
F
1
9
0
L
 
(
H
)
*
1
3
x
1
3
/
1
3
x
1
3
;
 
O
U
 
e
d
e
m
a
2
2
/
2
4
O
U
N
o
H
a
z
y
 
m
e
d
i
a
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
4
3
R
3
9
0
H
 
(
h
)
 
G
3
2
9
D
 
(
h
)
*
1
2
x
1
2
/
1
2
x
1
2
2
2
/
2
6
O
U
O
U
0
.
8
:
1
 
O
U
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
4
4
T
e
r
@
2
2
3
(
h
)
1
4
x
1
4
/
1
4
x
1
4
2
6
/
2
4
O
U
N
o
0
.
8
:
1
/
0
.
9
:
1
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
U
P
C
G
 
0
4
5
E
2
2
9
K
 
(
h
)
,
 
R
3
9
0
H
 
(
h
)
1
2
x
1
2
/
1
2
x
1
2
.
5
2
0
/
2
2
O
U
N
o
0
.
5
:
1
/
0
.
5
:
1
M
e
d
i
c
a
l
 
a
n
d
 
1
X
T
r
a
b
/
T
r
a
b
 
O
U
T
h
e
 
a
g
e
 
o
f
 
o
n
s
e
t
 
f
o
r
 
a
l
l
 
i
n
d
i
v
i
d
u
a
l
s
 
w
a
s
 
b
y
 
b
i
r
t
h
.
 
A
b
b
r
e
v
i
a
t
i
o
n
s
;
 
H
:
 
H
o
m
o
z
y
g
o
u
s
 
m
u
t
a
t
i
o
n
;
 
h
:
 
h
e
t
e
r
o
z
y
g
o
u
s
 
m
u
t
a
t
i
o
n
;
 
O
D
-
r
i
g
h
t
 
e
y
e
;
 
O
S
-
l
e
f
t
 
e
y
e
;
 
O
U
-
b
o
t
h
 
e
y
e
s
;
X
-
t
i
m
e
s
;
 
T
r
a
b
/
T
r
a
b
,
 
c
o
m
b
i
n
e
d
 
t
r
a
b
e
c
u
l
o
t
o
m
y
 
a
n
d
 
t
r
a
b
e
c
u
l
e
c
t
o
m
y
;
 
P
K
-
p
e
n
e
t
r
a
t
i
n
g
 
k
e
r
a
t
o
p
l
a
s
t
y
;
 
N
P
L
-
n
o
 
p
e
r
c
e
p
t
i
o
n
 
o
f
 
l
i
g
h
t
;
 
N
A
-
n
o
t
 
a
v
a
i
l
a
b
l
e
.
Molecular Vision 2009; 15:1200-1209 <http://www.molvis.org/molvis/v15/a128> © 2009 Molecular Vision
1204COOH-terminal (residues 528–543) in CYP1B1 did not have
corresponding equivalent regions in CYP2c9 from where the
structure  of  the  human  CYP1B1  protein  was  determined
[14]. Leucine is conserved in the CYP1B1 protein among
different species (Figure 6). Thus, we can hypothesize that
leucine plays an important role in determining the structure
and thus function of this protein.
Methionine132Arginine (M132R)—The mutation site
lies in the heme-binding region (HBR), which bridges helices
B’ and C. In the wild type protein, methionine extends in the
interior and packs between the I-helix (between N-319 and
Y-349) and one of the heme propionate groups. The amino
group (NH2) of M-132 donates a hydrogen bond (hb) to D-326
of the I-helix and accepts a hb from G-135, W-141, and R-468,
thus interconnecting the I-helix, C-helix, and heme binding
loop (HBL) [15]. Replacement of methionine by arginine
leads  to  congestion  of  this  packing,  thereby  potentially
harming the H-bond interaction.
Phenylalanine190Leucine (F190L)—The amino acid at
position  190  lies  between  the  alpha  helix  D  and  E.
Phenylalanine is conserved in the CYP1B1 protein among
different  species  (Figure  6).  Phenylalanine  contains  an
Figure 5. DNA sequence from intron 1 and exon 2 of CYP1B1. A:
Reference  sequence  derived  from  a  control  is  shown.  B:  DNA
sequence  derived  from  PCG  040  shows  the  homozygous  C>T
(38156048C→T)  nucleotide  change,  an  already  reported
polymorphism (rs2617266).
Figure 6. Multiple sequence alignment of various members of the
cytochrome P450 super-family. Red letters indicate the conserved
residues,  which  cause  the  congenital  glaucoma  phenotype  when
mutated.
aromatic ring while leucine contains an aliphatic group. So
this amino acid substitution may lead to structural alterations
in the CYP1B1 protein.
Termination@223—In this mutation, nucleotide A is
inserted in the cDNA at position 376, resulting in a frame-shift
that truncates the open reading frame (ORF) by creating a
premature stop codon (TGA) 636 bp downstream from the
insertion  site.  Consequently,  a  222  amino  acid  protein  is
produced, which lacks 321 amino acids from the COOH-
terminal. Both the wild type and the mutant proteins contain
just 10 amino acids at the NH2-terminus, which are similar in
both, and the frame-shift eliminated all CYP1B1 domains,
resulting in a functionally null allele [8].
Glutamic acid 229Lysine (E229K)—Position 229 lies
in a key region, contributing to the three-dimensional structure
of  the  protein  [15].  This  mutation  occurs  in  the  COOH-
terminal of the F-helix in the vicinity of the substrate binding
region (SBR). Substitution of E to K leads to a change from a
negatively charged residue to a positively charged side chain
and this in turn affects the local charge distribution. This
mutation disturbs an important cluster of salt bridges. In wild
type (WT), R-194::E-229, R-194::D-333, and D-333::K-512
form a triangle of ionic bond interactions, holding I-helix with
F-helix  and  β-strand  S3.2.  Due  to  this  mutation,  the
R-194::E-229  interaction  is  lost  and  has  the  potential  to
destabilize the other ionic interactions in the protein [15].
Glycine329Aspartic acid (G329D)—Gly329 is located
in the conserved I-helix of the CYP1B1 protein in different
species (Figure 6). Glycine is the smallest and most simple
amino acid whereas aspartic acid contains a CH2COO- acidic
group. Replacement of glycine by aspartic acid may cause
conformational changes in the protein. Ala330Phe was the
first missense mutation reported in this domain [16]. This
mutation represents the second missense mutation detected in
this domain.
Arginine368Histidine  (R368H)—The  residue  lies  in
between the helices J and K in an exposed loop [1,8,17].
Consequences of this change are not immediately apparent
except  that  the  positively  charged  amino  acid  arginine  is
replaced by histidine whose charge state depends upon its
protonation state. In the WT, arginine at 368 interacts with
G-365, D-367, V-363, and D-374. Because of the R368H
mutation,  interactions  between  D-367  and  D-374  are
weakened.  How  this  affects  the  conformation  and
functionality of the protein is still not clear [15].
Arginine390Histidine (R390H)—The residue is located
in the conserved alpha helix K [8]. It forms the consensus
sequence, GluXXArg, which is absolutely conserved among
all  members  of  the  cytochrome  P450  super  family  [12].
Arg390  and  Glu387  are  one  helical  turn  apart  and  are
predicted to form a salt bridge. The parallel orientation of their
side  chains  is  more  transparent  in  the  three-dimensional
model. Conservation of this motif indicates that it is essential
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1205for the normal function of the P450 molecule. However, the
exact function is still unclear [12].
DISCUSSION
PCG is a clinically and genetically heterogeneous disorder. In
familial cases, PCG is usually autosomal recessive. Recent
genetic studies from India, Saudi Arabia, and Brazil reported
several mutations in the coding region of CYP1B1. More than
40 different mutations have been reported in the entire coding
region of CYP1B1 [18-20], and genetic heterogeneity varies
with the population. The Slovak Gypsy population showed
allelic homogeneity and phenotypic uniformity [21] while
other  population  studies  reported  high  clinical  and  allelic
heterogeneity. Among these groups, higher homogeneity was
present in the Saudi Arabian population (with 72% having the
p.G61E allele and 12% the p.R469W allele) [19] whereas
other  populations  demonstrated  increased  genetic
heterogeneity. High homogeneity reflects the higher rate of
inbreeding in the population.
CYP1B1  codes  for  a  543  amino  acid  protein  and  is
expressed in the ocular tissues, in the anterior chamber of eye,
and  in  non-ocular  tissues  like  the  kidney  and  liver  [22].
CYP1B1 is a member of the cytochrome P450 super family
of drug metabolizing enzymes. It catalyzes several oxidative
reactions,  some  of  which  are  biosynthetic,  producing
necessary  hormones  or  compounds  of  intermediary
metabolism in most living organisms [23]. It acts on a wide
range of substrates including many xenobiotics, vitamins, and
steroids.  Reactions  catalyzed  by  the  enzyme  include
hydroxylation,  sulfoxidation,  N-,  S-,  and  O-dealkylations,
desulfation, deamination, and reduction of azo, nitro, and N-
oxide groups [24]. It also metabolizes vitamin A in two steps
to all-trans-retinal and all-trans-retinoic acid. The latter is a
potent  morphogen  and  regulates  in  utero  development  of
tissue growth and differentiation [25-27]. It is involved in the
metabolism of the endogenous and exogenous substrates that
take part in early ocular differentiation. Any mutation in this
gene can thus cause ocular development defects and result in
trabecular  dysgenesis  as  was  seen  in  our  patients  on  an
ultrastructural study (unpublished).The same morphological
alterations  have  been  reported  in  CYPIB1-deficient  mice
[28]. Membrane-bound cytochromes such as CYP1B1 have
molecular  structures  containing  a  transmembrane  domain
located  at  the  NH2-terminal  end  of  the  molecule.  This  is
followed  by  a  proline-rich  “hinge”  region,  which  permits
flexibility between the membrane-spanning domain and the
cytoplasmic portion of the protein molecule [29]. The COOH-
terminal ends are highly conserved among different members
of the cytochrome P450 super family. They contain a set of
conserved core structures (CCS) responsible for the heme-
binding region of these molecules. The heme-binding region
is essential for the normal function of every P450 molecule.
Between the hinge region and the CCS lies a less conserved
substrate-binding  region.  The  cytochrome  P450  protein
functions like any classical enzyme molecule.
Mutations  affecting  such  enzymes  generally  produce
recessive phenotypes because in heterozygous subjects, the
normal allele is capable of compensating for the mutant allele.
Mutations  in  CYP1B1  interfere  with  the  integrity  of  the
CYP1B1  molecule  as  well  as  its  ability  to  adopt  normal
conformation  and  to  bind  heme,  for  example,  induced
mutations in the hinge region have previously been reported
to  interfere  with  the  heme-binding  properties  of  the
cytochrome P450 molecules [25,26]. CYP1B1 participates in
the  normal  development  and  functioning  of  the  eye  by
metabolizing essential molecules that are probably used in a
signaling  pathway  [26].  Thus,  normal  development  and
differentiation of the anterior segment is important for normal
ocular  function,  and  mutations  in  CYPIB1  result  in  the
malformation  of  anterior  chamber  structures,  which
dramatically  affect  visual  function  by  blocking  aqueous
outflow.
CYPIB1 was originally identified as a dioxin-responsive
cDNA clone, and its activity against various xenobiotics and
pro-carcinogens  has  been  intensively  investigated  [30].  A
novel  TCDD  (2,3,7,8-tetrachlorodibenzo-p-dioxin)
responsive cDNA isolated from a human keratinocyte line has
been  identified  as  a  new  cytochrome  P450  super  family
member  [31].  This  human  protein  was  designated  as
cytochrome P450 (CYP1B1). It has also been identified and
cloned from mouse [32] and rat [33]. The estimated size of
rodent CYP1B1 mRNA (5.2 kb) is nearly identical to the
human CYP1B1 mRNA (5.1 kb), and each predicts a protein
of 543 amino acids. CYP1B1 is constitutively expressed in
the  adrenals,  ovary,  and  testis  and  is  inducible  by  planar
aromatic  hydrocarbons,  adrenocorticotropin,  and  peptide
hormones  [31,34].  It  is  involved  in  the  metabolism  of
xenobiotics and possibly steroid hormones as suggested by its
tissue distribution pattern [34,35].
In our study, 18% cases harbored the Ter@223 mutation.
This mutation has been reported previously from southern
India [8]. Earlier studies showed a very severe phenotype and
poor prognosis with the Ter@223 mutation. In this study, one
patient (PCG 017) was homozygous for the mutation, and two
(PCG 034 and PCG 041) were compound heterozygotes for
the Ter@223 and R390H mutations, and one patient (PCG
039) was a compound heterozygote for the Ter@223 and
R368H mutations. Five patients (PCG 019, PCG 021, PCG
029, PCG 040, and PCG 044) were heterozygous for the
Ter@223 mutation mutation. Congenital glaucoma is known
to be an autosomal recessive disorder, but it is difficult to
explain  the  disease  pathogenesis  in  these  five  patients.
Variants in both CYPIB1 and myocilin (MYOC) have been
detected  in  PCG,  indicating  higher  complexity  in  the
pathogenesis of this disease [36]. We have already screened
these  cases  for  mutations  in  MYOC  (unpublished).  These
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1206cases did not harbor any mutations in the myocilin gene. It is
possible that these cases harbor some mutations at some other
loci that have yet to be identified.
All patients with a CYP1B1 mutation had the p.L432V
polymorphism, and it has been reported that the CYP1B1
protein  with  valine  at  position  432  generates  more  free
radicals  and  causes  oxidative  damage  to  retinal  pigment
epithelial cells [37]. In five patients (PCG 019, PCG 021, PCG
029,  PCG  040,  and  PCG  044)  who  had  the  Ter@223
heterozygous  mutation,  we  can  hypothesize  that  in  these
cases, one truncated CYP1B1 protein is produced, which is a
functionally null protein, and that the second allele produces
a  protein,  which  generates  high  reactive  oxygen  species
(ROS) levels and thus causes oxidative stress-induced neural
degeneration. Neural crest cells appear to be a particularly
vulnerable cell population and are easily killed by compounds
such  as  retinoic  acid  [38].  It  has  also  been  reported  that
developing neural crest cells are deficient in glutathione and
catalase, two important antioxidant enzymes [39] that are
responsible for scavenging free radicals that damage cells.
Therefore,  it  is  possible  that  the  developing  trabecular
meshwork  suffers  oxidative  damage,  which  may  be  the
underlying  mechanism  for  trabecular  dysgenesis.  Three
patients (PCG 034, PCG 041, and PCG 039) had Ter@223
(heterozygous) with R390H and R368H mutations, and this
combination may produce one functionally null protein and
one defective CYP1B1 protein. All patients with Ter@223
(homozygote)  and  Ter@223  with  p.  R390H/R368H
(compound heterozygote) mutations showed no perception of
light  even  after  glaucoma  surgery.  Little  improvement  in
vision (light perception only) following glaucoma surgery
was observed in all five cases with heterozygous Ter@223
mutation whereas other patients with homozygous/compound
heterozygote CYP1B1 mutations showed no improvement at
all.
In  our  study,  p.R390H  is  the  second  most  common
mutation found in 16% of patients. This mutation had been
reported  in  other  populations  [13].  But  p.R390H  is  not
reported from the southern Indian population. Mutations at
position  390  emerged  as  a  hot  spot  for  mutations  in
CYP1B1. Mutations p.R390H, p.R390C, and p.R390S have
been reported from different populations [13]. Earlier studies
showed that prognosis of patients with a p.R390H mutation is
poorer than with a p.R390C mutation. Patients with the p.
R390H mutation showed little or no improvement in vision
compared to patients with the p.R390C mutation. Patients
with  the  p.R368H  homozygous  mutation  had  no  light
perception while one patient with the R368H heterozygous
mutation  showed  little  improvement  in  vision  following
surgery.
One patient (PCG 022) was a 10-month-old girl from a
non-consanguineous Hindu family who harbored a p.L24R
mutation.  She  had  bilateral  buphthalmos  with  raised
intraocular pressure (IOP) in both eyes (left; 24 mmHg and
right; 30 mmHg). The corneal diameter was 15 mm x 15 mm
in the left eye and 16 mm x 16 mm in the right eye with a
cup:disc ratio of 0.5:1 and 0.6:1 in the left and right eye,
respectively.  She  underwent  bilateral  trabeculotomy  and
trabeculectomy twice within a period of four months and is
able to fix onto and follow light.
Three-dimensional  models  from  Bacillus  magaterium
(CYP108 and CYP102 protein) were used in earlier studies to
determine the structure of the CYP1B1 protein, and these
studies  showed  that  the  first  49  amino  acids  were  not
conserved in the protein from the cytochrome 450 families
[14]. Multi-alignment of different CYP1B1 proteins showed
that  leucine  is  conserved  at  position  24  and  may  play  a
significant role in protein functioning [Figure 1]. Another
patient (PCG 022) with the CYP1B1 p.L24R mutation only
had bilateral buphthalmos with raised intraocular pressure. It
is possible that p.L24R is a pathogenic mutation that shows
improvement post-surgery and thus has a good prognosis,
though further functional studies are required to ascertain the
pathogenic role of the p. L24R mutation.
Patient  (PCG042)  harbored  p.F190L  mutation,  was  a
five-day-old child from a non-consanguineous Muslim family
with bilateral buphthalmos at birth with raised IOP (22 mmHg
in both eyes) and corneal diameter of 13 mm x 13 mm with
severe bilateral corneal edema. Fundus examination was not
possible  because  of  the  corneal  edema.  This  patient  was
heterozygous for the p.R368H (homozygous) and p.F190L
mutations. Due to compound heterozygous status, a defective
CYP1B1  protein  is  produced,  and  the  patient  showed  no
improvement in vision following surgery.
Another patient (PCG 043) had congenital glaucoma at
birth with IOPs of 22 and 26 mmHg in the right and left eye,
respectively, with corneal diameter of 12 mm x 12.5 mm with
presence of Haab’s striae in both eyes. She was a compound
heterozygote for the p.G329D (heterozygous) and p.R390H
(heterozygous)  mutations.  It  has  been  previously  reported
[13] that the p.R390H mutation produces a defective CYP1B1
protein as the glycine residue is conserved at this position in
the alpha I helix, thus a nucleotide change at this locus can
create a defective protein. Since congenital glaucoma is an
autosomal  recessive  disorder  and  both  mutations  are
heterozygous in this case, we can say that the combination of
both mutations produces a defective protein, which is unable
to perform its function. Hence, we can say p.G329D is a
pathogenic mutation.
In  our  study,  46%  of  patients  harbored  CYP1B1
mutations. This is slightly higher than the southern Indian
population  (43.5%)  but  lower  than  the  Slovak  gypsy
population  (100%)  [7,21].  Both  p.G61E  and  p.P193L
mutations were not present in our population while these were
present in congenital glaucoma patients from southern India
[8]. We found no significant differences between patients with
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1207homozygous CYP1B1 mutations and patients with compound
heterozygote  CYP1B1  mutations.  However,  patients  with
heterozygous CYP1B1 mutations had a better prognosis after
surgery  than  patients  with  homozygous/compound
heterozygous CYP1B1 mutations.
The  mutation  spectrum  of  northern  Indian  congenital
glaucoma  patients  is  totally  different  from  the  mutation
spectrum  of  southern  Indian  patients.  The  most  prevalent
mutation, p. R368H, in the southern population is present in
only 8% (4/50) of our patients while other mutations like
p.Ter@223  and  p.R390H  emerged  as  the  most  prevalent
CYP1B1 mutation in northern Indian patients. This difference
in the mutation spectrum of both the populations may be
explained  on  the  basis  of  different  ethnicity  of  both
populations  (Figure  1).  The  northern  Indian  population  is
predominantly Aryan population while the southern Indian
population is Dravidian with totally different morphological
phenotype and genetic background.
Three  novel  mutations  were  identified  in  this  study.
Studies  of  pathogenic  sequence  variants  of  CYP1B1  in
different populations may contribute to a better insight into
the molecular pathogenesis of congenital glaucoma. The new
mutations found in our study as well as those already reported
could also add to the existing repertoire of the SNPs, which
can be used in the future as diagnostic or prognostic markers
for detection and to chart the path of disease progression. This
will further help in the elucidation of the structure-function
relationship  of  CYP1B1  and  hence  may  lead  to  the
development  of  novel  therapeutics  in  management  of
congenital glaucoma in familial cases.
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